Hbm Holdings Stock price
Compare with Peer Group
Is Hbm Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Hbm Holdings Stock Analysis
Analyst Opinions
9 Analysts have issued a Hbm Holdings forecast:
Analyst Opinions
9 Analysts have issued a Hbm Holdings forecast:
Don't miss a Thing! We will send you all news about Hbm Holdings directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
HBM Holdings Ltd. is an investment company, which engages in the discovery and development of differentiated antibody therapeutics in oncology and immunology disease areas. The company is headquartered in Suzhou, Jiangsu and currently employs 237 full-time employees. The company went IPO on 2020-12-10. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The firm provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
| Head office | Cayman Islands |
| CEO | Dr. Jingsong |
| Employees | 272 |
| Website | www.harbourbiomed.com |


